ORYZON Secures €30M to Accelerate Innovational Epigenetics Therapies in Oncology and CNS Disorders

We are delighted to announce that Oryzon Genomics, S.A. has successfully raised €30,000,000 in its latest funding round, further fueling our mission to advance personalized medicine through epigenetics-based therapeutics. As the European leader in this innovative field, Oryzon is paving the way for transformational treatments in central nervous system (CNS) disorders and oncology. Since our founding in 2000 and listing on the Spanish Stock Exchange in 2015, we have continually attracted specialized investors from the US, Israel, and across Europe, all of whom share our vision for pioneering breakthroughs in biopharmaceutical research. This significant capital infusion will be dedicated to accelerating the development and clinical validation of our groundbreaking compounds. Presently, we are advancing two promising candidates in clinical trials: iadademstat – a highly potent LSD1 inhibitor currently in Phase IIa for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat – a CNS-optimized LSD1 inhibitor undergoing multiple Phase II trials for various CNS and psychiatric diseases. Additionally, our robust pipeline includes ORY-3001, a selective LSD1 inhibitor in preclinical development, as well as other programs targeting diverse epigenetic mechanisms for non-oncological conditions. With this new funding, we plan to expand our clinical trial capabilities and prepare for Phase IIb studies, further enhancing our state-of-the-art biomarker identification and target validation platforms. This investment not only amplifies our commitment to tackling some of the most challenging diseases but also strengthens our position as a leading force in the future of personalized therapies. We are excited to continue our journey of innovation and discovery, driving forward advancements that could redefine patient care across multiple therapeutic areas.